drugset / Trial / NCT03308552

Summary

This phase III trial is designed to explore a higher radiation dose by using IMRT simultaneous integrated boost technique with or without concurrent chemotherapy for esophageal carcinoma with limited lymph node metastasis.

Timeline

Start
2017-12-01
Primary completion
2020-08-30
Completion
2021-08-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cisplatin Other / unclassified 20 mg/m2
Comparator Cisplatin Other / unclassified 25 mg/m2
Comparator Cisplatin Other / unclassified 50 mg/m2
Comparator Cisplatin Other / unclassified 80 mg/m2
Comparator Lobaplatin Small molecule 20 mg/m2
Comparator Lobaplatin Small molecule 25 mg/m2
Comparator Lobaplatin Small molecule 50 mg/m2
Comparator Lobaplatin Small molecule 50 mg
Comparator Lobaplatin Small molecule 80 mg/m2
Comparator Nedaplatin Small molecule 20 mg/m2
Comparator Nedaplatin Small molecule 25 mg/m2
Comparator Nedaplatin Small molecule 50 mg/m2
Comparator Nedaplatin Small molecule 80 mg/m2
Comparator Paclitaxel Small molecule 45 mg/m2
Comparator Paclitaxel Small molecule 50 mg/m2
Comparator Paclitaxel Small molecule 150 mg/m2

Indications